Emerging Markets Earnings Roundup: Merck, AstraZeneca (Part 6)
This article was originally published in PharmAsia News
Executive Summary
Merck comes up short on goal to reach 25% of total sales from emerging markets and sees headwinds on diabetes. AstraZeneca is full-steam ahead on China with headcount expansion in 2013 paving the way for gains in 2014, CEO Pascal Soriot says.